Maker of a wearable cardioverter defibrillator that monitors and treats patients at risk of sudden cardiac arrest.
Maker of a wearable cardioverter defibrillator that monitors and treats patients at risk of sudden cardiac arrest.
Rents the wearable device to patients for a prescribed period, usually billing their health insurers rather than the patient, so insurer coverage decisions matter as much as doctor adoption. Each prescription lasts only until the patient's heart recovers or a permanent implant is fitted, so revenue depends on a steady flow of newly prescribed patients.
In one line: A newer rival to ZOLL's LifeVest wearable defibrillator.
Moat: narrow (IP / patents, regulatory licence). One of few FDA-cleared wearable defibrillators, competing directly with the long-established ZOLL LifeVest.
Headquarters: Kirkland, Washington · Founded: 2012 · Employees: 443
Size Kestra Medical Technologies (KMTS) is a United States Health Care company (Medical Specialties) with a market value of $1.69B, the 1886th largest of 3,085 United States companies the cockpit tracks. Shares closed at $28.29 on 18 Nov 2026.
Performance Over six months the shares gained 36.3%, against -2.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 60.7% over the last twelve months (peer median +8.2%); the operating margin is -134.5% (peer median 13.6%).
Valuation It trades at 14.6× enterprise value to sales against a peer median of 2.9× (2nd most expensive of 21).
Capital Return on invested capital runs 120.8 points below its cost of capital (7.3% WACC).
Short interest Short interest is 6.9% of the free float (30 Oct 2026).
Next results Next results expected around 10 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $107M | $95.1M | $59.8M | $27.8M | $7.63M |
| Revenue growth | — | +59% | +115% | +265% | — |
| Gross profit | $57.5M | $48.9M | $24.2M | $362,000 | -$10.7M |
| EBITDA | -$134M | -$126M | -$98.4M | -$73.5M | -$75.6M |
| Net income | -$150M | -$132M | -$114M | -$94.1M | -$84.2M |
| Free cash flow | -$123M | -$117M | -$101M | -$84.7M | -$85.1M |
| Capital expenditure | $35.5M | $35.4M | $23.6M | $12.5M | $15.5M |
| Total debt | $76.4M | $46.8M | $44.3M | $45.2M | $39.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Kestra Medical Technologies KMTS | $1.69B | +36% | +61% | -134% | 14.6× | n/a |
| Medtronic MDT | $129B | +30% | +10% | 20% | 4.0× | 9.1% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 3.5× | 5.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KMTS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | 0.0% | -5.2% | 8th highest of 21 |
| 6-month return | +36.3% | -2.3% | 3rd highest of 21 |
| Distance from 52-week high | -11.6% | -26.7% | 2nd highest of 21 |
| Revenue growth (TTM) | +60.7% | +8.2% | 2nd highest of 21 |
| Operating margin | -134.5% | 13.6% | lowest of 21 |
| EV / Sales | 14.6× | 2.9× | 2nd most expensive of 21 |
| ROIC minus cost of capital | -120.8 pp | +0.9 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | 14.6× | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 1.6× | 28.7% | +51.2% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 1.1× | 11.2% | +1.9% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 1.3× | n/a | n/a |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 2.2× | -1.9% | +8.3% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 5.5× | 16.4% | +12.9% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 5.7× | 2.9% | +14.0% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | 12.3× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 3.0× | 16.7% | +25.8% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 23.1× | 19.4% | +12.7% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 2.1× | 11.2% | +7.4% |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 2.8× | 4.8% | +19.7% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 7.7× | n/a | n/a |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 6.9× | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 4.9× | 22.2% | +22.5% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 1.3× | 20.0% | -6.0% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 0.8× | -12.6% | +2.1% |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 0.9× | -3.5% | +3.3% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 5.7× | 2.7% | +23.4% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 1.6× | -1.6% | -1.0% |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 3.5× | 18.3% | +14.5% |